Reports Q1 revenue $2.33B, consensus $2.2B. "In the first quarter we delivered double digit year-over-year revenue growth in our base business, driven by strong performance across our physician and hospital customers," said Jim Davis, chairman, CEO and president. "We are excited about our announced acquisition of Haystack Oncology, which supports our molecular genomics and oncology strategy in the fast growing category of minimal residual disease testing."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
- Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
- Quest Diagnostics (DGX) Q1 Earnings Cheat Sheet
- Quest Diagnostics and NewYork-Presbyterian Complete Laboratory Services Acquisition
- Quest Diagnostics upgraded to Neutral from Sell at Citi